WO2024170976 - CODON OPTIMIZED POLYNUCLEOTIDE ENCODING HUMAN FACTOR IX
National phase entry is expected:
Publication Number
WO/2024/170976
Publication Date
22.08.2024
International Application No.
PCT/IB2024/050692
International Filing Date
25.01.2024
Title **
[English]
CODON OPTIMIZED POLYNUCLEOTIDE ENCODING HUMAN FACTOR IX
[French]
POLYNUCLÉOTIDE À CODON OPTIMISÉ CODANT POUR LE FACTEUR IX HUMAIN
Applicants **
INTAS PHARMACEUTICALS LTD.
Corporate House, Near Sola Bridge,
S. G. Highway, Thaltej, Ahmedabad - 380054,
Gujarat, IN
Inventors
MISHRA, Niraj
Intas Pharmaceuticals Limited – Biopharma Division, Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad-382213.
Gujarat, IN
BASAK, Shashwati
Intas Pharmaceuticals Limited – Biopharma Division, Plot No: 423/P/A/GIDC, Vill: Moraiya
Sarkhej-Bavla Highway, Ta:Sanand,
Ahmedabad-382213.
Gujarat, IN
Priority Data
202321011083
18.02.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 953 | |
| EPO | Filing, Examination | 6366 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 4510 |
Total: 12993 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to polynucleotide comprising codon optimized nucleotide encoding human Factor IX protein. The method of treatment of hemophilia by administering polynucleotide comprising codon optimized nucleotide encoding human Factor IX protein wherein, the activity of human Factor IX of the present invention is higher than the wild type human Factor IX.[French]
La présente invention concerne un polynucléotide comprenant un nucléotide à codon optimisé codant pour la protéine du facteur IX humain. Le procédé de traitement de l'hémophilie consiste à administrer un polynucléotide comprenant un nucléotide à codon optimisé codant pour la protéine du facteur IX humain, l'activité du facteur IX humain de la présente invention étant supérieure à celle du facteur IX humain de type sauvage.